CD274 and cancer: These findings can help policymakers weigh the benefits of incorporating anti-PD-(L)1 agents into treatment guidelines for early-stage cancer and support discussions around investment in anti-PD-(L)1 agents in the adjuvant/neoadjuvant setting.